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ABSTRACT
Background: The discovery of abnormal synchroniza-
tion of neuronal activity in the basal ganglia in Parkin-
son’s disease (PD) has prompted the development of
novel neuromodulation paradigms. Coordinated reset
neuromodulation intends to specifically counteract
excessive synchronization and to induce cumulative
unlearning of pathological synaptic connectivity and
neuronal synchrony.
Methods: In this prospective case series, six PD
patients were evaluated before and after coordinated
reset neuromodulation according to a standardized
protocol that included both electrophysiological
recordings and clinical assessments.
Results: Coordinated reset neuromodulation of the
subthalamic nucleus (STN) applied to six PD patients
in an externalized setting during three stimulation days
induced a significant and cumulative reduction of beta
band activity that correlated with a significant improve-
ment of motor function.
Conclusions: These results highlight the potential
effects of coordinated reset neuromodulation of the
STN in PD patients and encourage further develop-
ment of this approach as an alternative to conventional
high-frequency deep brain stimulation in PD. VC 2014
The Authors. Movement Disorders published by Wiley
Periodicals, Inc. on behalf of International Parkinson
and Movement Disorder Society.
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Deep brain stimulation (DBS) of the subthalamic
nucleus (STN) is a well-established treatment for
patients with advanced Parkinson’s disease (PD),1,2
Novel stimulation approaches, for instance, closed-loop
neurostimulation that have only been tested in an acute
setting, turned out to be more effective than classical
DBS in reducing motor signs as well as pallidal firing
rate and oscillatory activity in parkinsonian nonhuman
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
treated primates and PD patients during stimulus
delivery.3,4
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Another original approach, electrical coordinated
reset (CR) neuromodulation,5,6 specifically targets PD-
related pathological neuronal synchrony7,8 by
desynchronization and is based on extensive computa-
tional5,6 and in vitro9 studies. Coordinated reset neu-
romodulation means to consecutively deliver brief
high-frequency pulse trains through the different stim-
ulation contacts of the implanted lead (see Supplemen-
tal Data Fig. S1) to sequentially reset the phases of the
different stimulated subpopulations and, hence, divide
the neuronal population into phase-shifted subpopula-
tions, ultimately causing an unlearning of both patho-
logical neuronal synchrony and pathological synaptic
connectivity.5,6,9 According to the model, CR neuro-
modulation of sufficient duration is expected to shift
the neuronal population into a stable desynchronized
state, characterized by downregulated synaptic con-
nectivity. Accordingly, one may speculate that neuro-
nal desynchronization along with positive effects on
motor control may outlast the CR neuromodulation
duration.
In both MPTP-treated monkeys10 and PD patients,11
only short-lasting aftereffects are observed when con-
ventional high-frequency neurostimulation is termi-
nated. In parallel, abnormal oscillatory activity and
neuronal synchrony reemerge shortly after turning off
classical DBS.8,12 In contrast, in MPTP-treated nonhu-
man primates, CR neuromodulation delivered to the
STN for 2 hours per day on 5 consecutive days had
both acute and sustained long-lasting aftereffects on
motor function for up to 30 days.10
As yet, physiological aftereffects of CR neuromodu-
lation of the STN on abnormal neuronal synchrony
were studied neither in MPTP monkeys nor in PD
patients, and a clinical proof-of-concept is lacking in
humans. Here we aimed to assess (1) initial safety and
tolerability of electrical CR neuromodulation, (2) ini-
tial estimation of the action of electrical CR neuromo-
dulation on the abnormal local field potential (LFP)
oscillations, (3) initial estimation of the action of elec-
trical CR neuromodulation on motor function of
patients with Parkinson’s disease in a small proof-of-
concept study of short duration. Specifically, we
hypothesize that CR neuromodulation causes a lasting
reduction of abnormal power in beta or theta fre-
quency bands in parallel with a reduction of motor
symptoms.5,6,10 Results of this study will provide
information necessary regarding potential trial end-
points and therapeutic regimen(s) for future controlled
trials of electrical CR neuromodulation.
Methods
Six patients (4 women and 2 men) aged 45 to 73
years (mean6 standard deviation, 61.3611.5 years)
with PD (2 with akinetic-rigid and 4 with equivalent
type; see Supplemental Data for the definition; mean-
6 standard deviation disease duration, 11.36 5.8
years) were selected for the study. The mean Unified
Parkinson’s Disease Rating Scale (UPDRS) motor
score (sum of the items 18-31, on medication) was
33.365.3 in the presurgery phase.13 The local ethical
committee approved the study design, and all patients
gave written informed consent. We set out to investi-
gate electrophysiological and neurological outcomes of
electrical CR neuromodulation of the STN in this
cohort of six PD patients.
All patients underwent bilateral implantation of
quadripolar deep-brain electrodes (Medtronic 3389)
into the STN, and stimulation was applied through
the externalized electrodes, using a portable external
stimulation and registration device.14 Medication was
suspended 2 days before starting test stimulation and
throughout the entire testing period. Coordinated
reset neuromodulation5 was applied for 3 consecutive
days in two daily sessions of up to 2 hours (mean
duration of each sessions was 1.660.3 hours; Fig.
1A) and consisted of brief high-frequency pulse trains
(intra-burst frequency: 130 Hz, intensity: 2.0-4.0
mA, cycle repetition rate 3-20 Hz, pulse width: 60-
120 ms, each pulse train was composed of 3 to 5 sin-
gle pulses, pulse train duration was 23-38 ms) that
were applied following the dedicated CR pattern (see
Supplemental Data Fig. S1) through the three lower
contacts of the stimulation electrode, and the upper
contact served as current return. Because of technical
constraints, CR neuromodulation was performed uni-
laterally, exclusively contralateral to the more
severely affected side.
Standardized evaluations using UPDRS motor scores
were undertaken in all patients 25 minutes before
(morning scores) and 25 minutes after (evening scores)
stimulation sessions (Fig. 1A) on every stimulation day
to assess motor performance before and after CR neu-
romodulation. The LFPs of the STN were recorded
before and after stimulation sessions on every stimula-
tion day according to the scheme presented in Fig. 1A.
We calculated the individual peak beta power (in the
8-35 Hz range), which is believed to be related to bra-
dykinesia and rigidity7,8 and individual theta power
(3-7 Hz), which corresponds to tremor frequency.15
The spectral power values were then normalized for
every patient separately and finally averaged over all
six patients.
Acute after-effects on beta (or correspondingly
theta) band activity and UPDRS motor scores achieved
within a single stimulation day were calculated with
the formula: (morning beta power2 evening beta
power)/morning beta power. To assess lasting afteref-
fects, that is, effects persisting overnight, we deter-
mined relative changes of quantities measured in the
morning of days 2 and 3 with respect to the baseline
value obtained in the morning of day 1, for example,
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FIG. 1. Effect of CR neuromodulation on normalized LFP activity and motor performance in six PD patients. Coordinated reset neuromodulation and
measurements followed the experimental scheme in (A) on each of the 3 stimulation days. Example of the raw LFP signal at baseline (B, first day
before stimulation) and after 3 days of CR neuromodulation (C, in the evening of the third day of stimulation) and the LFP power spectrum (D)
obtained from the patient 3 where an extended spontaneous LFP was obtained before and 1 hour after cessation of CR neuromodulation illustrate
the effect of CR neuromodulation. The normalized reduction of UPDRS motor scores and the reduction of the averaged beta band power obtained
at the third stimulation day (E, after stimulation) were positively correlated. Effects of CR neuromodulation on normalized individual LFP activity and
individual motor performance in six PD patients (F, G, H, I) on the evening of the third day of stimulation. Patients 1 and 2 did not show tremor, and
therefore theta band activity was not analyzed in these two patients. The averaged normalized beta band power (K), the average normalized theta
band power (L, obtained from the 4 patients with tremor), as well as UPDRS motor score (items 18-31) (M) and UPDRS motor score subitems 20
through 26 (N), improved cumulatively and consistently over 3 days of stimulation. Wilcoxon matched-pairs test was performed to evaluate changes
of LFP activity and scores. Significant results are marked by the star (P< 0.05). Please note, because of the small sample size of this exploratory
proof of concept study, the statistical analysis has limited explanatory power. Therefore, the beneficial clinical effects observed in all subjects con-
sistently are of more importance. Abbreviations: CR, coordinated reset; LFP, local field potential; UPDRS, Unified Parkinson’s Disease Rating Scale.
(baseline beta2beta in the morning of day 2)/baseline
beta. In addition, if a repeated administration of CR
neuromodulation produces effects that are more pro-
nounced than those produced by the first daily CR
neuromodulation dose, such as leading to better
improvement in the evening on day 3 as opposed to
the evening on day 1, we term these effects cumula-
tive. A Wilcoxon matched pairs test was performed to
evaluate changes in LFP activity and UPDRS scores.
See Supplemental Data for a detailed description of
the methods.
Results
All six enrolled subjects received CR neuromodula-
tion during 3 stimulation days. The averaged peak
beta power decreased gradually over the 3 stimulation
days, resulting in a mean reduction of 42.0%,
P5 0.03/48.0%, P5 0.03 in the morning/evening of
day 3 relative to baseline in all six patients (Fig. 1F,
K; Table 1). Acute CR-induced effects were already
observed on day 1 in five patients (mean reduction,
22.8%; P5 0.046, n5 6; Fig. 1K, Table 1), with a
mean acute aftereffect on the peak beta band power
TABLE 1. Absolute and relative changes in beta and theta activity and UPDRS motor scores in 6 patients over the 3-d
period of CR neuromodulationa
Day 1 Day 2 Day 3
Morning
assessment
(before stimulation)
Evening
assessment
(after stimulation)
Morning
assessment
(before stimulation)
Evening
assessment
(after stimulation)
Morning
assessment
(before stimulation)
Evening
assessment
(after stimulation)
Beta activity Mean (SD), a.u 0.99 (0.02) 0.76 (0.28) 0.74 (0.27) 0.54 (0.27) 0.57 (0.17) 0.51 (0.07)
Change from base-
line, mean (%)c
- 22.8% 25.1% 44.9% 42.0% 48.0%
Significanceb - 0.046 0.12 0.03 0.03 0.03
Number/percentage
of patients with
beta activity reduc-
tion (%)
- 5/83.3 4/66.6 6/100.0 6/100.0 6/100.0
Theta activity Mean (SD), a.u. 0.95 (0.10) 0.65 (0.25) 0.60 (0.18) 0.34 (0.32) 0.63 (0.29) 0.43 (0.13)
Change from base-
line, mean (%)c
- 29.2% 35.7% 61.2% 32.0% 53.0%
Significanceb - 0.14 0.07 0.07 0.07 0.07
Number/percentage
of patients with
theta activity reduc-
tion (%)
- 3/75.0 4/100.0 4/100.0 4/100.0 4/100.0
UPDRS total
motor score
18-31
Mean (SD) 27.0 (16.2) 20.5 (11.1) 22.0 (10.12) 16.5 (9.4) 17.8 (9.9) 12.0 (8.15)
Change from base-
line, mean (%)c
- 18.1 7.2 34.8 24.1 58.0
Significanceb - 0.08 0.11 0.03 0.07 0.03
Number/percentage
of patients showing
improvements (%)
- 4/66.6 4/66.6 6/100.0 5/83.3 6/100.0
UPDRS tremor
subscore
20-21
Mean (SD) 9.8 (4.9) 6.8 (3.1) 6.8 (2.2) 6.8 (2.9) 6.0 (3.6) 3.5 (1.7)
Change from base-
line, mean (%)c
- 23.7 24.3 24.8 38.5 60.4
Significanceb - 0.07 0.04 0.046 0.07 0.03
Number/percentage
of patients showing
improvements (%)
- 2/50.0 3/75.0 3/75.0 4/100.0 4/100.0
UPDRS
bradykinesia/
rigidity
subscore
22-26
Mean (SD) 14.8 (9.5) 11.0 (7.0) 12.3 (7.1) 8.2 (5.9) 9.3 (6.6) 6.0 (4.8)
Change from base-
line, mean (%)c
- 22.0 13.0 43.5 34.0 63.1
Significanceb - 0.046 0.43 0.01 0.03 0.01
Number/percentage
of patients showing
improvements (%)
- 5/83.3 4/63.3 6/100.0 6/100.0 6/100.0
a.u., arbitrary units.
aA positive change from baseline indicates a reduction (i.e., an improvement) in physiological activity and UPDRS motor scores.
bWilcoxon matched pairs test. Comparison vs baseline.
cPercentual changes were calculated for each patient individually (compared with the individual baseline) and averaged afterward. Positive values indicate a
reduction.
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averaged over the 3 stimulation days of 16.1%
(P5 0.04). Effects of CR neuromodulation on the LFP
theta band power are presented in Figure 1G, L, and
Table 1. The acute theta change averaged over the 3
stimulation days was 32.1% (P50.02).
The UPDRS motor score averaged over six patients
on the morning of the first day was 27.06 16.2
(P5 0.72 compared with pre-implantation scores) and
served as baseline. In the morning of the third day
before stimulation, the UPDRS motor scores were
reduced in five patients (mean reduction, 24.1%;
P5 0.07, n56), followed by a more pronounced
improvement in all six patients on the third day after
stimulation (mean reduction, 58.0%; P50.03, n5 6;
Fig. 1H, M, and Table 1). Tremor-related UPDRS
motor score subitems 20 to 21 were reduced in all
four patients presenting with tremor by an average of
60.4% (P50.03, n5 4) on the evening of the third
day, whereas the UPDRS motor score subitems 22
through 26 (rigidity and bradykinesia) were reduced
in all six patients (mean reduction, 63.1%; P5 0.01,
n5 6), respectively (Table 1 and Fig. 1I). Coordinated
reset neuromodulation showed significant acute after-
effects (averaged over the 3 stimulation days in all
patients, 26.8%, P50.03). The reduction of UPDRS
motor scores positively correlated with the decrease in
individual beta band peak power (Fig. 1E; r5 0.83;
P5 0.041; n5 6), whereas theta band power did not
show such a correlation. No adverse events were
observed.
Discussion
We show here in PD patients that CR neuromodu-
lation has significant as well as cumulative afteref-
fects on beta LFP oscillations that were positively
correlated with a reduction of motor symptoms. All
six patients responded well to CR neuromodulation.
Our results are in accordance with theoretical pre-
dictions,5,6 in vitro experiments9, preclinical results
in MPTP monkeys,10 and pathophysiological findings
relating abnormal neuronal synchrony to motor
signs.7,8 The CR effects on motor symptoms and
abnormal brain oscillations are quite consistent. Beta
oscillations7,8 and corresponding UPDRS subitems
22 through 26 were reduced in all six patients in the
morning and evening of the third day. In addition,
tremor-related theta LFP oscillations15 and UPDRS
subitems 20 and 21 were reduced in all four patients
with tremor in the morning and evening of the
third day.
The electrophysiological and clinical CR effects,
observed in all six patients (reduction of LFP beta
activity by 48% and of UPDRS motor scores by 58%
compared with baseline), were cumulative; that is,
after the third daily dose of CR neuromodulation (in
the evening of day 3) UPDRS motor scores showed a
significant improvement (P50.03), and beta activity
showed a trend toward a significant reduction
(P50.08) compared with the evening of the first day.
This cumulative improvement is particularly remark-
able, because it is in the opposite direction of the
worsening typically observed (personal observations)
as a consequence of the fading insertional effect.
Despite limitations because of the small sample size,
the non-blinded, open-label design, missing high-
frequency or placebo comparison, and short treatment
duration, our conclusive electrophysiological data,
correlated with clinical improvement confirm, previ-
ous theoretical5,6 and experimental9,10 data and ena-
ble one to elaborate effects of CR neuromodulation
of the STN in PD patients. The risk of a type I error
attributable to multiple statistical comparisons is also
present. Of course, the effects of electrical CR neuro-
modulation have to be confirmed in a randomized
controlled trial. However, conducting randomized
controlled trials and developing the corresponding
implantable device for electrical CR neuromodulation
require substantial investments. Proof-of-concept
studies such as ours are, hence, key for the overall
decision making as well as for the design of future tri-
als. Should appropriate randomized controlled trials
ultimately confirm the encouraging preliminary results
shown here, electrical CR neuromodulation could rep-
resent a substantial advancement for the treatment of
Parkinson’s disease.
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Abstract
Background: Families of Dutch-German-Russian Men-
nonite descent with multi-incident parkinsonism have
been identified as harboring a pathogenic DNAJC13
p.N855S mutation and are awaiting clinical and patho-
physiological characterization.
Methods: Family members were examined clinically
longitudinally, and 5 underwent dopaminergic PET
imaging. Four family members came to autopsy.
Results: Of the 16 symptomatic DNAJC13 mutation
carriers, 12 had clinically definite, 3 probable, and 1
possible Parkinson’s disease (PD). Symptoms included
bradykinesia, tremor, rigidity, and postural instability,
with a mean onset of 63 years (range, 40-85) and slow
progression. Eight of ten subjects who required treat-
ment had a good levodopa response; motor complica-
tions and nonmotor symptoms were observed.
Dopaminergic PET imaging revealed rostrocaudal stria-
tal deficits typical for idiopathic PD in established dis-
ease and subtle abnormalities in incipient disease.
Pathological examinations revealed Lewy body
pathology.
Conclusion: PD associated with a DNAJC13 p.N855S
mutation presents as late-onset, often slowly progres-
sive, usually dopamine-responsive typical PD. VC 2014
International Parkinson and Movement Disorder
Society
Key Words: Parkinson’s disease (PD); Positron Emis-
sion Tomography (PET); Lewy Body Pathology;
DNAJC13; Mennonite; familial PD
Parkinson’s disease (PD) has a comparatively high
prevalence in Mennonite communities, with a relative
frequency 4.8-fold higher than other North American
Caucasian populations.1 Recently, a pathogenic muta-
tion in DNAJC13 (receptor-mediated endocytosis 8)
was linked with autosomal-dominant parkinsonism in
Mennonites.2 By whole-exome sequencing, DNAJC13
p.N855S was observed in 3 symptomatic family mem-
bers (pedigree SK1 II-7, III-4, and III-14). Subsequent
Sanger sequencing and genotyping showed the muta-
tion segregated with parkinsonism and identified 2
more multi-incident pedigrees (BC1 and SK2) and 2
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